Do You Know What Biogen Inc.’s (NASDAQ:BIIB) P/E Ratio Means?

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We’ll show how you can use Biogen Inc.’s (NASDAQ:BIIB) P/E ratio to inform your assessment of the investment opportunity. Biogen has a P/E ratio of 10.47, based on the last twelve months. That is equivalent to an earnings yield of about 9.6%.

See our latest analysis for Biogen

How Do I Calculate Biogen’s Price To Earnings Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Or for Biogen:

P/E of 10.47 = $226.39 ÷ $21.62 (Based on the year to December 2018.)

Is A High P/E Ratio Good?

The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. That isn’t necessarily good or bad, but a high P/E implies relatively high expectations of what a company can achieve in the future.

How Growth Rates Impact P/E Ratios

Probably the most important factor in determining what P/E a company trades on is the earnings growth. That’s because companies that grow earnings per share quickly will rapidly increase the ‘E’ in the equation. Therefore, even if you pay a high multiple of earnings now, that multiple will become lower in the future. So while a stock may look expensive based on past earnings, it could be cheap based on future earnings.

Biogen’s earnings made like a rocket, taking off 81% last year. The cherry on top is that the five year growth rate was an impressive 22% per year. With that kind of growth rate we would generally expect a high P/E ratio.

How Does Biogen’s P/E Ratio Compare To Its Peers?

We can get an indication of market expectations by looking at the P/E ratio. The image below shows that Biogen has a lower P/E than the average (19.2) P/E for companies in the biotechs industry.

NasdaqGS:BIIB Price Estimation Relative to Market, April 19th 2019
NasdaqGS:BIIB Price Estimation Relative to Market, April 19th 2019

Its relatively low P/E ratio indicates that Biogen shareholders think it will struggle to do as well as other companies in its industry classification. Many investors like to buy stocks when the market is pessimistic about their prospects. If you consider the stock interesting, further research is recommended. For example, I often monitor director buying and selling.

A Limitation: P/E Ratios Ignore Debt and Cash In The Bank

Don’t forget that the P/E ratio considers market capitalization. That means it doesn’t take debt or cash into account. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

Spending on growth might be good or bad a few years later, but the point is that the P/E ratio does not account for the option (or lack thereof).

How Does Biogen’s Debt Impact Its P/E Ratio?

Biogen’s net debt is 5.4% of its market cap. So it doesn’t have as many options as it would with net cash, but its debt would not have much of an impact on its P/E ratio.

The Bottom Line On Biogen’s P/E Ratio

Biogen’s P/E is 10.5 which is below average (18.2) in the US market. The company does have a little debt, and EPS growth was good last year. The low P/E ratio suggests current market expectations are muted, implying these levels of growth will not continue. Because analysts are predicting more growth in the future, one might have expected to see a higher P/E ratio. You can taker closer look at the fundamentals, here.

Investors have an opportunity when market expectations about a stock are wrong. If it is underestimating a company, investors can make money by buying and holding the shares until the market corrects itself. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.